Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PDA I > Exam 5 > Flashcards

Exam 5 Flashcards

1
Q

mechlorethamine, melphalan, ifosfamide, cyclophosphamide, chlorambucil - class

A

nitrogen mustards - DNA damaging agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

carmustine, streptozoxin - class

A

nitrosoureas - DNA damaging agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

oxaliplatin, carboplatin, cisplatin - class

A

platinum coordination complexes - DNA damaging agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

mechlorethamine, melphalan, ifosfamide, cyclophosphamide, chlorambucil, carmustine, streptozoxin, oxaliplatin, carboplatin, cisplatin - Target

A

causes intra/interstrand cross links

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

mechlorethamine, melphalan, ifosfamide, cyclophosphamide, chlorambucil, carmustine, streptozoxin, oxaliplatin, carboplatin, cisplatin - biochemical/physiological responses

A

inability of cell to separate DNA, initiation of DNA repair mechanisms
cell can’t replicate DNA or make proteins - cell undergoes apoptosis if can’t repair in time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

mechlorethamine, melphalan, ifosfamide, cyclophosphamide, chlorambucil, carmustine, streptozoxin, oxaliplatin, carboplatin, cisplatin - adverse effects

A

hematological (myelosuppression), hepatotoxicity, nephrotoxicity, neurotoxicity, nausea, dehydration, malnutrition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

mechlorethamine, melphalan, ifosfamide, cyclophosphamide, chlorambucil, carmustine, streptozoxin, oxaliplatin, carboplatin, cisplatin - interactions

A

TNF blockers, clozapine, deferiprone, leflunomide, zidovudine, thalidomide, nephrotoxic agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

temozolomide, decarbazine - class

A

triazenes- DNA damaging agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

temozolomide, decarbazine - target

A

addition of methyl group to DNA bases (guanine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

temozolomide, decarbazine - biochemical/physiological

A

incorrect DNA base matching during replication
loss of DNA fidelity - leads to mutation and loss of protein function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

temozolomide, decarbazine - adverse effects

A

hematological (myelosuppression), immunosuppression, hepatotoxicity, nausea, dehydration, malnutrition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

temozolomide, decarbazine - interactions

A

TNF blockers, clozapine, deferiprone, leflunomide, zidovudine, thalidomide, nephrotoxic agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

daunorubicin, doxorubicin, idarubicin - class

A

anthracycline antibiotics - DNA damaging agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

daunorubicin, doxorubicin, idarubicin - target

A

intercalates into DNA and inhibits topoisomerase 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

daunorubicin, doxorubicin, idarubicin - biochemical/physiological

A

inability to replicate DNA or make proteins, initiates DNA repair mechanisms
halt of DNA cell cycle progression, loss of cellular function - cell undergoes apoptosis if can’t repair DNA in time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

daunorubicin, doxorubicin, idarubicin - adverse effects

A

hematological, cardiovascular, nausea, dehydration, malnutrition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

daunorubicin, doxorubicin, idarubicin - interactions

A

clozapine, deferiprone, TNF blockers, leflunomide, thalidomide, prolongs QT interval

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

bleomycin, mitomycin - class

A

anthracenedione antibiotics - DNA damaging agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

bleomycin, mitomycin - target

A

intercalates into DNA causing DNA crosslinks and double/single strand breaks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

bleomycin, mitomycin - biochemical, physiological

A

inability to replicate DNA or make proteins, initiates DNA repair mechanisms
halt of DNA cell cycle progression, loss of cellular function - cell undergoes apoptosis if can’t repair in time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

bleomycin, mitomycin - adverse effects

A

hematological, nausea, dehydration, malnutrition, nephrotoxicity, lung fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

bleomycin, mitomycin - interactions

A

clozapine, deferiprone, TNF blockers, leflunomide, thalidomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

methotrexate - class

A

DNA replication - antimetabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

methotrexate - target

A

competitive inhibitor of dihydrofolate reductase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
methotrexate - biochemical/physiological
inability to convert DHF into active THF, can't convert dUMP to dTMP no new strands of DNA (loss of monomers), loss of proliferation
26
methotrexate - adverse effects
hematological (myelosuppression), nephrotoxicity, hepatotoxicity
27
methotrexate - interactions
other nephrotoxic agents, trimethoprim, clozapine, deferiprone, TNF blockers
28
capecitabine, floxuridine - class
DNA replication - antimetabolites
29
capecitabine, floxuridine - target
inhibition of thymidylate synthase
30
capecitabine, floxuridine - biochemical, physiological
inability of cell to synthesize dTMP from dUMP cell can't create new strands of DNA (loss of proliferation)
31
capecitabine, floxuridine - adverse effects
hematological, nausea, dehydration, malnutrition
32
capecitabine, floxuridine - interactions
clozapine, deferiprone, TNF blockers, leflunomide, thalidomide
33
cytarabine - class
DNA replication - antimetabolite
34
cytarabine - target
inhibits DNA polymerase
35
cytarabine - biochemical/physiological
cells can't synthesize new DNA cells can't replicate DNA
36
cytarabine - adverse effects
hematological, pancreatitis, nausea, dehydration, malnutrition, neurotoxicity
37
cytarabine - interactions
clozapine, deferiprone, TNF blockers, leflunomide, thalidomide
38
mercaptopurine, thioguanine - class
DNA replication - antimetabolites
39
mercaptopurine, thioguanine - target
inhibits DNA polymerase, inhibits de novo purine synthesis
40
mercaptopurine, thioguanine - biochemical/physiological
cells can't synthesize new DNA/proteins cells can't replicate DNA
41
mercaptopurine, thioguanine - adverse effects
hematological, hyperuricemia due to nephrotoxicity, hepatotoxicity
42
mercaptopurine, thioguanine - interactions
clozapine, deferiprone, ribavirin, TNF blockers, leflunomide, thalidomide, azathioprine
43
cladribine - class
DNA replication - antimetabolite
44
cladribine - target
causes inhibition of DNA polymerase and strand breaks
45
cladribine - biochemical/physiological
cells can't synthesize DNA/proteins, initiates DNA repair mechanisms cells can't replicate DNA or make proteins - cell undergoes apoptosis if can't repair in time
46
cladribine - adverse effects
hematological
47
cladribine - interactions
TNF blockers, leflunomide
48
gemcitabine, fludarabine - class
DNA replication - antimetabolites
49
gemcitabine, fludarabine - target
inhibits RR and DNA polymerase
50
gemcitabine, fludarabine - biochemical/physiological
inability of cells to create deoxyribonucleosides (RR inhibition), inability of cells to create DNA (DNA polymerase inhibition) cells can't replicate DNA
51
gemcitabine, fludarabine - adverse effects
hematological, pulmonary distress, hepatotoxicity, neurotoxicity
52
gemcitabine, fludarabine - interactions
clozapine, deferiprone, TNF blockers, leflunomide, thalidomide
53
hydroxyurea - class
DNA replication - antimetabolite
54
hydroxyurea - target
inhibits RR
55
hydroxyurea - biochemical/physiological
cells can't synthesize deoxyribonucleosides cell can't synthesize new DNA
56
hydroxyurea - adverse effects
neurotoxicity, hematological, hepatotoxicity, nausea, dehydration, malnutrition
57
hydroxyurea - interactions
clozapine, deferiprone, TNF blockers, leflunomide, thalidomide
58
pentostatin - class
DNA replication - antimetabolite
59
pentostatin - target
inhibits adenosine deaminase - disruption of nucleic acid metabolism resulting in inhibition of RR
60
pentostatin - biochemical/physiological
cells can't make deoxyribonucleosides cells can't make new DNA
61
pentostatin - adverse effects
hematological, nausea, dehydration, malnutrition
62
pentostatin - interactions
clozapine, deferiprone, TNF blockers, thalidomide
63
bortezomib - class
DNA replication - antimetabolite
64
bortezomib - target
inhibits 26S proteasome
65
bortezomib - biochemical/physiological
cell can't degrade proteins - particularly those with rapid turnover/pro-apoptotic proteins induction of apoptosis due to presence of apoptotic proteins
66
bortezomib - adverse effects
peripheral neuropathy, cardiovascular, hematological
67
bortezomib - interactions
deferiprone
68
irinotecan, topotecan - class
DNA replication - topoisomerase inhibitors
69
irinotecan, topotecan - target
inhibits topoisomerase 1
70
irinotecan, topotecan - biochemical/physiological
cells can't unwind DNA cells can't replicate DNA or make proteins
71
irinotecan, topotecan - adverse effects
hematological, hepatotoxicity, nephropathy, nausea, dehydration, malnutrition
72
irinotecan, topotecan - interactions
clozapine, deferiprone, TNF blockers, leflunomide, thalidomide, CYP3A4 substrate
73
etoposide, teniposide - class
DNA replication - topoisomerase inhibitors
74
etoposide, teniposide - target
inhibits topoisomerase 2
75
etoposide, teniposide - biochemical/physiological
cells can't unwind DNA cells can't replicate DNA or make proteins
76
etoposide, teniposide - adverse effects
hematological, cardiovascular, nausea, dehydration, malnutrition
77
etoposide, teniposide - interactions
clozapine, deferiprone, TNF blockers, leflunomide, thalidomide
78
vinblastine, vincristine - class
mitotic inhibitors
79
vinblastine, vincristine - target
inhibits polymerization of tubulin into microtubules
80
vinblastine, vincristine - biochemical/physiological
inability of cells to form microtubules and separate cell components equally parent cell cannot divide into 2 daughter cells
81
vinblastine, vincristine - adverse effects
hematological, neuropathy, nausea, dehydration, malnutrition
82
vinblastine, vincristine - interactions
clozapine, deferiprone, TNF blockers, leflunomide, thalidomide, CYP3A4 substrate
83
paclitaxel, docetaxel - class
mitotic inhibitors
84
paclitaxel, docetaxel - target
inhibits depolymerization of microtubules into tubulin
85
paclitaxel, docetaxel - biochemical/physiological
cells can't pull components of cell apart during mitosis parent cell cannot divide into 2 daughter cells
86
paclitaxel, docetaxel - adverse effects
hematological, peripheral neuropathy
87
paclitaxel, docetaxel - interactions
clozapine, deferiprone, TNF blockers, leflunomide, thalidomide, CYP3A4 substrate
88
tamoxifen, toremifene - class
hormone receptor antagonists
89
tamoxifen, toremifene - target
estrogen receptor antagonist
90
tamoxifen, toremifene - biochemical/physiological
inability of cells to transcribe genes under control of estrogen receptor cells can't proliferate or evade immune system
91
tamoxifen, toremifene - adverse effects
menopause-like symptoms (hot flashes, sweating, nausea, vaginal discharge, dizziness, vomiting), hematological, cardiovascular
92
tamoxifen, toremifene - interactions
prolongs QT interval, toremifene (substrate of CYP3A4), tamoxifen (substrate of CYP2D6)
93
anastrozole, exemestane, letrozole - class
hormone receptor antagonists
94
anastrozole, exemestane, letrozole - target
inhibits enzyme aromatase
95
anastrozole, exemestane, letrozole - biochemical/physiological
cells can't produce estrogen from precursors cells can't activate estrogen receptor - results in ability to proliferate and evade immune system
96
anastrozole, exemestane, letrozole - adverse effects
menopause-like symptoms (hot flashes, sweating, vaginal discharge, dizziness, vomiting), hematological, hepatotoxicity, cardiovascular
97
anastrozole, exemestane, letrozole - interactions
thalidomide, letrozole CYP2C19 inhibitor
98
nilutamide, flutamide - class
hormone receptor antagonists
99
nilutamide, flutamide - target
androgen receptor antagonists
100
nilutamide, flutamide - biochemical/physiological
cells can't transcribe genes under control of androgen receptor cells can't proliferate and evade immune system
101
nilutamide, flutamide - adverse effects
hepatotoxicity, nausea, dehydration, malnutrition
102
nilutamide, flutamide - interactions
none severe
103
gefitinib, erlotinib - class
protein tyrosine kinase inhibitors
104
gefitinib, erlotinib - target
inhibition of EPIDERMAL growth factor receptor
105
gefitinib, erlotinib - biochemical/physiological
cells can't initiate growth factor cascade cells can't proliferate or metastasize - increase in cellular apoptosis
106
gefitinib, erlotinib - adverse effects
hematological, pulmonary toxicity, nausea, dehydration, malnutrition
107
gefitinib, erlotinib - interactions
clozapine, deferiprone, TNF blockers, leflunomide
108
imatinib - class
protein tyrosine kinase inhibitor
109
imatinib - target
inhibits bcr-abl chimeric tyrosine kinase
110
imatinib - biochemical/physiological
cells can't initiate growth factor signal cascade cells can't proliferate or metastasize - increase in cellular apoptosis
111
imatinib - adverse effects
hematological, cardiovascular
112
imatinib - interactions
clozapine, deferiprone, TNF blockers, leflunomide, CYP 3A4, 2D6, 2C9 inhibitor
113
trastuzumab - receptor
HER2/ErbB-2 EPIDERMAL growth factor receptor
114
bevacizumab - receptor
VEGFR1/2 (vascular-ENDOTHELIAL growth factor)
115
cetuximab - receptor
EPITHELIAL growth factor receptor
116
trastuzumab, bevacizumab, cetuximab - target
inhibits over-expressed antigens on cell surface
117
trastuzumab, bevacizumab, cetuximab - biochemical/physiological
cells can't initiate growth factor signal cascade cells can't proliferate or metastasize - increase in cellular apoptosis
118
rituximab - receptor
CD20
119
alemtuzumab - receptor
CD52
120
nivolumab - receptor
PD1
121
durvalumab - receptor
PD-L1
122
rituximab, alemtuzumab, nivolumab, durvalumab - target
binding to overexpressed antigen - directs immune system to initiate a response
123
rituximab, alemtuzumab, nivolumab, durvalumab - biochemical/physiological
immune system mediated initiation of apoptosis signal cascade immune system directed cell lysis or apoptosis of neoplastic cell
124
ibritumomab - receptor
CD20
125
brentuximab - receptor
CD30
126
ibritumomab, brentuximab - target
binding to overexpressed antigen - release of conjugated radioactive particle/chemotherapeutic (DNA damaging agent)
127
ibritumomab, brentuximab - biochemical/physiological
inability to replicate DNA or make proteins, initiates DNA repair mechanisms halt of DNA cell cycle progression, loss of cellular function - cell undergoes apoptosis if can't repair in time
128
all immune system modulators - adverse effects, interactions
hematological, cardiovascular clozapine, TNF blockers, leflunomide, thalidomide

PDA I (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions